Oramed Pharmaceuticals Inc (ORMP) - Total Assets
Based on the latest financial reports, Oramed Pharmaceuticals Inc (ORMP) holds total assets worth $268.85 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ORMP cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Oramed Pharmaceuticals Inc - Total Assets Trend (2005–2025)
This chart illustrates how Oramed Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Explore Oramed Pharmaceuticals Inc (ORMP) investment intensity to see how much of total assets are deployed in long-term investments.
Oramed Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Oramed Pharmaceuticals Inc's total assets of $268.85 Million consist of 57.7% current assets and 42.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.9% |
| Accounts Receivable | $4.64 Million | 2.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Oramed Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Oramed Pharmaceuticals Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oramed Pharmaceuticals Inc's current assets represent 57.7% of total assets in 2025, a decrease from 100.0% in 2005.
- Cash Position: Cash and equivalents constituted 19.9% of total assets in 2025, up from -3209.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 2.0% of total assets.
Oramed Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Oramed Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Oramed Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.45 | 23.94 | 12.56 |
| Quick Ratio | 6.45 | 23.94 | 12.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $57.59 Million | $125.98 Million | $66.48 Million |
Oramed Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Oramed Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.65 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | 48.7% |
| Total Assets | $230.86 Million |
| Market Capitalization | $149.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oramed Pharmaceuticals Inc's assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Oramed Pharmaceuticals Inc's assets grew by 48.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Oramed Pharmaceuticals Inc (2005–2025)
The table below shows the annual total assets of Oramed Pharmaceuticals Inc from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $230.86 Million | +48.68% |
| 2024-12-31 | $155.28 Million | -29.60% |
| 2023-12-31 | $220.55 Million | +36.44% |
| 2022-12-31 | $161.64 Million | +26.28% |
| 2021-12-31 | $128.00 Million | +186.78% |
| 2020-12-31 | $44.63 Million | +28.76% |
| 2019-12-31 | $34.66 Million | -26.87% |
| 2018-12-31 | $47.40 Million | +22.43% |
| 2017-12-31 | $38.71 Million | -9.61% |
| 2016-12-31 | $42.83 Million | +62.52% |
| 2015-12-31 | $26.35 Million | +20.88% |
| 2014-12-31 | $21.80 Million | +151.75% |
| 2013-12-31 | $8.66 Million | +63.56% |
| 2012-12-31 | $5.29 Million | +22.40% |
| 2011-12-31 | $4.33 Million | +198.16% |
| 2010-12-31 | $1.45 Million | -55.52% |
| 2009-12-31 | $3.26 Million | -40.77% |
| 2008-12-31 | $5.51 Million | +184.31% |
| 2007-12-31 | $1.94 Million | +999.38% |
| 2006-12-31 | $176.19K | +13883.33% |
| 2005-12-31 | $1.26K | -- |
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for C… Read more